Metabotropic Glutamate Receptor 7 drugs in development by Therapy Areas, Indications, Stages, MoA, RoA, Molecule Type, and Key Players, 2023

The report also covers products from therapy areas such as Central Nervous System, Women’s Health, Genetic Disorders, and Undisclosed which include the indications Post-Traumatic Stress Disorder (PTSD), Opium (Opioid) Addiction, Post Partum Depression (Maternal Depression / Postnatal Depression), DiGeorge Syndrome, and Unspecified. It also reviews key players involved in Metabotropic Glutamate Receptor 7 targeted therapeutics development with respective active and dormant or discontinued products.

The Metabotropic Glutamate Receptor 7 pipeline targets constitutes close to seven molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, and Preclinical stages are 2, and 3 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.

Metabotropic Glutamate Receptor 7 overview

Metabotropic glutamate receptor 7 is a protein encoded by the GRM7 gene. G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase.

For a complete picture of Metabotropic Glutamate Receptor 7’s drug pipeline, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.